BioSpace News Archive

Neon Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) and hopes to raise $115 million.

The ink is barely dry on the recently-passed “Right to Try Act,” and the law’s author, Sen. Ron Johnson (R-Wis.) and U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb are butting heads.

Amgen, and The University of Texas MD Anderson Cancer Center, announced two multi-year collaborative research deals for a broad range of cancer therapeutics.

FDA Commissioner Scott Gottlieb released a statement on new policies aimed to combat the practice of using certain agency requirements to block timely generic drug entry.

AbbVie announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA® (ibrutinib) plus RITUXAN® (rituximab).

Menarini Ricerche will present at ASCO Annual Meeting 2018 the study design of CD205-Shuttle

- First-in-human safety data presented from phase 1/2 study with U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with heavily pretreated HER3-positive metastatic breast cancer - Preliminary efficacy data demonstrated a 47 percent confirmed overall response rate and a 94 percent disease control rate with U3-1402

MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation

SilverCloud Health Limited has updated the user interface (UI) for its digital mental health platform.

Vaxart, Inc. announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference.